Skip to content
Maria C. McGreevy, M.D.

Maria C. McGreevy, M.D.


UR Medicine Faculty The University of Rochester Medical Faculty Group (URMFG) consists of over 900 specialist and primary care providers spanning 19 departments. URMFG is certified by the National Committee for Quality Assurance.
Accountable Health Partner Accountable Health Partners (AHP) is a network of over 2,000 community and UR medical faculty and a dozen leading hospitals throughout the region. AHP offers a full range of care.
Accepting New Patients


About Me

Faculty Appointments

Assistant Professor - Department of Medicine, Hematology/Oncology (SMD)


Residency & Fellowship

Fellowship, Hematology & Oncology, University of Rochester Medical Center. 2019 - 2022

Residency, Internal Medicine, University of Virginia GME. 2016 - 2019


MD | SUNY Upstate Medical University College of Medicine. 2016


Segel/Haterman Fellowship Award. 2021

Hematology Oncology Chief Fellow. 2021 - 2022

First Place Oral Presentation, American College of Physicians Virginia Resident Abstract Competition. 2019

Junior year Alpha Omega Alpha Society. 2015

James Stacy Coles Fellow. 2008 - 2009

Sarah and James Bowdoin Scholar. 2007 - 2008


Clinical Trials

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Lead Researcher: Maria C McGreevy

This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.


Journal Articles

Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses.

Brown JR, Walker SR, Heppler LN, Tyekucheva S, Nelson EA, Klitgaard J, Nicolais M, Kroll Y, Xiang M, Yeh JE, Chaudhury M, Giaccone ZT, Fernandes SM, Jacobsen ED, Fisher DC, Freedman AS, Davids MS, Supko JG, Wu C, Frank DA

American journal of hematology.. 2021 April 196 (4):E95-E98. Epub 01/11/2021.

CDK5RAP3 is a co-factor for the oncogenic transcription factor STAT3.

Egusquiaguirre SP, Liu S, Toši? I, Jiang K, Walker SR, Nicolais M, Saw TY, Xiang M, Bartel K, Nelson EA, Frank DA

Neoplasia : an international journal for oncology research.. 2020 January 22 (1):47-59. Epub 11/22/2019.

The transcriptional modulator BCL6 as a molecular target for breast cancer therapy.

Walker SR, Liu S, Xiang M, Nicolais M, Hatzi K, Giannopoulou E, Elemento O, Cerchietti L, Melnick A, Frank DA

Oncogene.. 2015 February 2634 (9):1073-82. Epub 03/24/2014.

Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells.

Weisberg E, Liu Q, Zhang X, Nelson E, Sattler M, Liu F, Nicolais M, Zhang J, Mitsiades C, Smith RW, Stone R, Galinsky I, Nonami A, Griffin JD, Gray N

PloS one.. 2013 8 (2):e56473. Epub 02/21/2013.

The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations.

Nelson EA, Walker SR, Xiang M, Weisberg E, Bar-Natan M, Barrett R, Liu S, Kharbanda S, Christie AL, Nicolais M, Griffin JD, Stone RM, Kung AL, Frank DA

Genes & cancer.. 2012 July 3 (7-8):503-11. Epub 1900 01 01.